(2 µM) also inhibited the BiFC signal (Supplementary Fig. 1b) . The OB-1 molecule was also resynthesized in house and exhibited the same activity in the BiFC assay as the commercially available sample. The human STOML3 peptide sequence is 92% identical to that of the mouse overall and 100% identical in the core stomatin domain, and human STOML3 also showed self-association (Fig. 1f) . More importantly for potential future clinical development, self-association of the human STOML3 protein was also inhibited by OB-1 (Fig. 1f) .
STOML3 oligomerization dictates domain size in the plasma membrane
We next asked whether OB-1 and OB-2 modulation of STOML3 oligomerization state influenced clustering of the protein in the plasma membrane. We used super-resolution dSTORM microscopy [19] [20] [21] to visualize FLAG-tagged (sequence motive: DYKDDDDK) STOML3 at the plasma membrane of transfected N2a cells. Using dSTORM, we showed that STOML3 was present in microdomains at the plasma membrane (Fig. 1g) . The size of the STOML3 clusters was variable (full width at half maximum = 24.6 ± 2.8 nm, mean ± s.e.m.; Fig. 1h ) but these domains may contain more than one STOML3 dimer 10 . Introduction of the V190P mutation disrupts oligomerization of STOML3 and abolishes its ability to modulate the mechanosensitivity of Piezo1 channels 2 . This STOML3 variant exhibited significantly smaller clusters in the plasma membrane (Fig. 1g,h) , demonstrating that we could manipulate and measure nanoscale changes in STOML3 cluster size by disrupting STOML3 oligomerization. Preincubation of N2a cells expressing STOML3-FLAG with OB-1 or OB-2 for three hours led to significantly reduced STOML3-FLAG cluster sizes compared to vehicle treated cells (Fig. 1g,h ). The effects of OB-1 did not produce changes in Stoml3 mRNA levels in these cells (Supplementary Fig. 2a ). Thus we obtained independent support for the notion that OB-1 and OB-2 reduce the STOML3 oligomerization state, an important consequence of which is a reduced STOML3 cluster size at the plasma membrane.
STOML3 inhibitors modulate mechanotransduction currents
Endogenously expressed STOML3 in N2a cells is required to maintain Piezo channel sensitivity to membrane deflection 2 . By precisely Each data point represents a single cell; the FHWM of 100 randomly chosen domains was measured for each cell. **P < 0.01; ***P < 0.001. a r t I C l e S deflecting defined areas of the membrane-substrate interface using a pillar array, we could activate Piezo1 currents in N2a cells with displacements ranging from 100 to 1,000 nm (Fig. 2a,b) . Both OB-1 and OB-2 reduced the sensitivity of mechanosensitive currents to pillar deflection (Fig. 2b) . Preincubation of cells with OB-1 for periods of between 1 and 3 h reduced Piezo1 current amplitudes, but the effect was only maximal after 3 h (Supplementary Fig. 2b ). Recording mechanically activated currents in the presence of different concentrations of OB-1 revealed a steep concentration dependence with a calculated half-maximal inhibitory concentration (IC 50 ) of 10 nM and Hill coefficient 0.6 (Fig. 2c) . Next, we evaluated the effects of OB-1 and OB-2 on mechanosensitive currents in acutely cultured mouse sensory neurons. Neurons were classified on the basis of their AP configuration as mechanoreceptors or nociceptors 2, 22 . We found that mechanically gated currents in mechanoreceptors start to activate with membrane deflections of <50 nm 2 , but this sensitivity was substantially reduced after exposure to OB-1 or OB-2 (Fig. 2d,e) . Thus robust mechanically gated currents were only observed in OB-1 or OB-2 treated cells with deflections that exceeded 100 nm. The threshold for activation of mechanosensitive currents in nociceptive sensory neurons is normally higher than that of mechanoreceptors 2 , a finding reproduced here (Fig. 2e,f) . However, we also observed that OB-1 or OB-2 treatment produced a significant reduction in the amplitude of mechanically gated currents in nociceptors with stimulus magnitudes between 100 and 500 nm (Fig. 2f) . In addition, the latency for mechanically gated currents, as well as a r t I C l e S the activation time constant for current activation, τ 1, was significantly slowed in nociceptors after treatment with OB-2 (latency, P= 0.0315; τ 1 , P= 0.001; Supplementary Fig. 2c,d ). Exposing N2a cells or sensory neurons to OB-1 for 3 h did not lead to any changes in the level of Stoml3 transcripts (Supplementary Fig. 2a ), suggesting that our molecules do not change gene expression or transcript stability. Cell soma indentation can also be used to evoke 'rapidly adapting currents' (inactivation constant τ 2 < 5 ms) in mechanoreceptor sensory neurons 22, 23 , and after exposure to OB-1, ~60% of the neurons (12/21 neurons) displayed no mechanosensitive current compared to control or vehicle-treated neurons (21%, 8/38 neurons); this effect was statistically significant (Fisher's exact test, P = 0.009; Supplementary  Fig. 3a-e) .
Neither of the two compounds tested had any discernible effects on voltage-gated currents or membrane excitability, as evidenced by the fact that APs were of normal amplitude and shape after treatment (Fig. 2h,i) . For example, cultured sensory neurons treated for at least 3 h with 20 µM OB-1 displayed no alteration in a number of parameters indicative of electrical excitability (Fig. 2g-i and Supplementary Table 1 ). In summary, using two independent assays, we found that OB-1 is a powerful inhibitor of native mechanosensitive currents. Stomatin-domain proteins can also negatively regulate members of the acid-sensing ion channel family (ASICs) in a subunit-specific manner 6, 10, 24, 25 . However, OB-1 had no detectable effect on the negative modulation of ASIC3 mediated currents by mouse stomatin (Supplementary Fig. 4) .
A STOML3 inhibitor can silence touch receptors Many cutaneous mechanoreceptors in Stoml3 −/− mice innervate the skin but cannot be activated by mechanical stimulation 5, 6 . We gave mice subcutaneous injections of OB-1 (250-500 pmol per paw) into hairy skin innervated by the saphenous nerve and recorded from sensory afferents 3 h later using an ex vivo skin-nerve preparation 5, 26 . In wildtype mice, the vast majority of myelinated and unmyelinated fibers are mechanosensitive [4] [5] [6] , as demonstrated by tracing the spike evoked by local electrical stimulation of nerve branches and then searching for the nearby mechanosensitive receptive field (Fig. 3a) . In contrast, in skin pretreated with OB-1, over 40% of Aβ fibers (19/44) lacked a mechanosensitive receptive field, and this was significantly different from what we found in vehicle-injected controls, where less than 7% (5/69 fibers) were found to be insensitive to mechanical stimuli (P < 0.0001, Fischer's exact test; Fig. 3a and Supplementary Table 2 ). Male and female mice displayed almost identical proportions of OB-1 treated Aβ fibers that were insensitive to mechanical stimuli (Fig. 3a) . Amongst Aδ fibers we also observed an increase in the proportion of fibers for which no mechanosensitive receptive field could be found (21% or 8/38 fibers, compared to 5% or 1/19 fibers in controls, but this was not significantly different; Fischer's exact test, P > 0.24). There was also no change in the proportion of C fibers that lacked a mechanosensitive receptive field (Fig. 3a) . We next examined the physiological properties of the remaining mechanosensitive afferents in OB-1 treated skin. However, the proportion of mechanoreceptor types found, as well as the mechanosensitivity of the remaining Aβ fiber mechanoreceptors (rapidly and slowly adapting mechanoreceptors), was unchanged compared to controls ( Supplementary Fig. 5a-e) . The mechanoreceptor silencing effect of local OB-1 treatment was completely reversible: recordings from afferents 24 h after treatment revealed no significant loss of mechanosensitivity compared to vehicle-treated skin (Fig. 3a) . Thus, a STOML3 oligomerization inhibitor can specifically and reversibly silence touch receptor activity without changing axonal excitability. Although we found no evidence that C-fiber nociceptors are silenced by OB-1 treatment (Fig. 3a) , we did note a statistically significant effect Figure 3 Mechanoreceptors can be silenced with local OB-1 treatment. (a) Inset: electrical search protocol schema. A microelectrode (~1 MΩ) was used to deliver electrical stimuli at two distant points of the saphenous nerve trunk in order to trace electrically identified units to their receptive fields. Proportions of non-mechanosensitive fibers are shown. We observed an increase in mechanically sensitive Aβ fibers 3 h after local OB-1 treatment (250-500 pmol OB-1 per paw); mechanosensitivity recovered 24 h after injection. Fisher's exact test for Aβ fibers: vehicle vs. OB-1 (male and female mice), P < 0.0001; vehicle vs. OB-1 (male), P < 0.0001; vehicle vs. OB-1 (female), P = 0.0033; OB-1 (male) vs. OB-1 (female) In a-e, numbers indicate single sensory fiber recordings derived from 10-20 independent experiments using adult mice. *P < 0.05; **P < 0.01; ***P < 0.001; ns, nonsignificant. a r t I C l e S of local OB-1 treatment on the mechanosensitivity of C-fiber afferents that respond to both thermal and mechanical stimuli (C-mechanoheat fibers, two-way ANOVA, P = 0.0412; Fig. 3b ). C-mechanoheat fibers also displayed significantly elevated mechanical thresholds for activation that were on average almost twice that of control fibers (196.5 ± 35.6 mN, mean ± s.e.m. in OB-1 treated skin versus 106.9 ± 17.4 mN, mean ± s.e.m. in vehicle-treated skin, Mann-Whitney U-test, P = 0.0233) as measured using a force measurement system attached to the stimulus probe (Fig. 3c) . The firing rates of C-mechanonociceptors that lack heat sensitivity in response to suprathreshold mechanical stimuli were not significantly attenuated in OB-1 treated skin (Fig. 3d, 
e).
Touch perception is attenuated by local OB-1 treatment We used a tactile perception task in head-restrained mice to assess the effects of OB-1 on touch sensation. Water-restricted mice were trained to press a sensor with their forepaw within 500 ms after the onset of a 30-ms cosine mechanical stimulus applied to the same paw. Correct responses were rewarded with water. Mice learned this task to a high degree of reliability after a 7-10 d training period (Fig. 4a ). Different stimulus amplitudes were then used to determine a psychometric curve for each mouse (Fig. 4a,b) . We next injected the drug vehicle solution into the forepaw and obtained a new psychometric curve for each mouse 3-5 h later. On the next day, the forepaw was injected with the OB-1 compound (11 nmol per paw) followed by behavioral testing. At least 24 h after the OB-1 testing day, the recovery behavior was tested without any prior injection. Following OB-1 treatment the psychometric curve was shifted to the right for stimulus strengths between 125 and 275 µm, indicating less reliable stimulus detection (Wilcoxon signed-rank test, vehicle versus OB-1, P = 0.026; OB-1 versus OB-1 wash-out, P = 0.0043; Fig. 4b,c) . Vehicle treatment produced no significant change in the psychometric curve (Wilcoxon signed-rank test, control versus vehicle, P = 0.30). The detection rates of threshold stimuli before and 1-4 d after treatment were not significantly different (Wilcoxon signed rank test, vehicle versus OB-1 wash-out, P = 0.12), suggesting it had returned to pretreatment levels.
These data indicate that silencing of a subset of mechanoreceptors via STOML3 inhibition is sufficient to reduce the reliability of near threshold touch perception in mice.
Peripheral STOML3 blockade reverses tactile allodynia
Neuropathic pain is a debilitating condition in which intense pain can be initiated by merely brushing the skin, activating low-threshold mechanoreceptors [7] [8] [9] 27, 28 . We used the chronic constriction injury model (CCI), which involves direct damage to sciatic nerve axons ( Supplementary Fig. 6a-f ) that innervate the hypersensitive plantar hindpaw skin. Baseline paw withdrawal thresholds in wild-type and Stoml3 −/− mice did not differ, as measured with von Frey hairs using an adapted up-down method 29 (Fig. 5a) . However, after induction of a unilateral CCI 9 , paw withdrawal thresholds dropped profoundly in wild-type mice but were only moderately reduced in Stoml3 −/− mice (two-way ANOVA, P < 0.001; Fig. 5a ). Thermal hyperalgesia also accompanies neuropathic injury 7, 9, 30 , a phenomenon that we also observed. However, the heat hyperalgesia observed in Stoml3 −/− mice was identical to that in wild-type controls (Fig. 5b) .
We next asked whether local application of OB-1 can ameliorate tactileevoked pain behavior in neuropathic models. We found no change in paw withdrawal thresholds to mechanical stimuli in the paws of naive mice treated with an intraplantar dose of OB-1 (250-500 pmol per paw; Fig. 5c ). However, when we applied an intraplantar dose of OB-1 to the paws of wild-type mice with established neuropathic pain (CCI model 6-21 d after induction) we observed a complete reversal of the tactile-evoked pain or allodynia (CCI, 0.00975 ± 0.02 g versus OB-1 treated, 0.7125 ± 0.12 g; P = 0.0002, Wilcoxon signed-rank test; Fig. 5d ). The effects of OB-1 were also indistinguishable between female and male mice with CCI (Fig. 5d) 31 . We also applied OB-1 to the contralateral paw at the same concentration that was effective at reversing allodynia present in the paw ipsilateral to the injury, but we observed no reversal of established hypersensitivity (Fig. 5e) . These results suggest that the actions of OB-1 in reversing hypersensitivity are due to inhibition of sensory neuron mechanotransduction in the skin Figure 4 OB-1 reduces touch perception in mice, as shown by performance of head-restrained mice on a tactile perception task. (a) Mice were trained to report a single tactile pulse stimulus (inset shows stimulus voltage command pulse for all 8 amplitudes). Trial structure: mice were trained to (1) hold the rest sensor and wait for a stimulus; (2) on detection of the stimulus reach and press the target sensor within 500 ms from stimulus onset; (3) obtain water reward by licking on successful trials. (b) Psychometric curves to different amplitude tactile stimuli are affected by injection of OB-1 into forepaw. Curves were constructed with a sigmoid fitting of the mean (n = 5 mice) hit rates to 7 different amplitudes of tactile stimuli and to a no stimulus trial (false alarm). Three conditions are displayed: injection of the vehicle (black), injection of OB-1 (magenta) and a recovery session with no prior injection (gray). (c) OB-1 application to forepaw attenuates perception of near threshold tactile stimuli. Grouped hit rates to three threshold amplitude values (125, 175 and 275 µm) from 5 mice were significantly reduced after OB-1 injection as compared to hit rates after vehicle injection or on recovery session without prior injection. Statistical tests were made on hit rates after subtraction of the corresponding false alarm rates. Wilcoxon signed-rank test: vehicle vs. OB-1, P = 0.026; OB-1 vs. OB-1 wash-out, P = 0.0043; vehicle vs. OB-1 wash-out, P = 0.12; numbers indicate mice treated, and data are displayed as average of individual hit rates of each mouse, grouped for 3 amplitudes ± s.e.m. *P < 0.05; **P < 0.01; ns, nonsignificant. a r t I C l e S and not to systemic or central actions. The reversal of tactile allodynia observed with local OB-1 treatment was indistinguishable from that found with systemic gabapentin treatment (Fig. 5f) , a standard, centrally acting drug in clinical use for the treatment of neuropathic pain 32 . Using a series of OB-1 concentrations we determined a halfmaximal effective dose (ED 50 ) of 4.42 µM (or approximately 20 pmol per paw; Fig. 5g) . The effects of a single OB-1 dose became maximal 3 h after the injections and wore off slowly over the next 12 h, so the effect was absent after 24 h (Fig. 5h) . To test the idea that OB-1 reversed mechanical hypersensitivity primarily by inhibiting STOML3 oligomerization, we tested the effects of local OB-1 on the mechanical sensitivity of Stoml3 −/− mice with CCI. Mechanical hypersensitivity following CCI is much less prominent in Stoml3 −/− mice (Fig. 5a,i) , but we observed no change in paw withdrawal threshold after treating neuropathic paws of Stoml3 −/− mice with OB-1 (Fig. 5i) . Off-target effects are an issue for any biologically active small molecule. We therefore tested the effects of 20µM OB-1 in a commercially available in vitro pharmacology panel (http://www.cerep.fr/Cerep/Utilisateurs/ index.asp) consisting of 79 receptors and ion channels (Supplementary Dataset 1). Substantial inhibition of specific ligand binding to the selected receptors was seen in a few cases (6/79), but there is at present no data implicating any of these receptors in peripheral nociception. The agreement between the in vitro and in vivo effects of STOML3 inhibition and the results of genetic ablation of Stoml3 in the mouse suggest that OB-1 exerts its biological effects primarily on STOML3. The remarkable protection from touch-evoked pain in animals lacking STOML3 led us to hypothesize that the nerve injury may itself lead to a change in the levels of Stoml3 mRNA expression in the dorsal root ganglia (DRG). Upregulation of STOML3 could in turn exacerbate touch-evoked pain by enhancing the sensitivity of mechanotransduction in injured sensory afferents. Using real-time quantitative PCR we measured a doubling in Stoml3 mRNA expression levels in the lumbar DRGs that project axons to the ligation site compared to the control uninjured side (P < 0.01, Mann-Whitney U-test; Fig. 5j ).
The CCI model involves direct damage to the axons that innervate the hypersensitive skin (in this case, the skin of the plantar hindpaw) 33 . Neuropathic touch hypersensitivity is also induced in the same skin area by cutting nerves adjacent to the tibial nerve, which innervates the plantar foot 34, 35 . Spared tibial nerve injury (SNI) mice develop a long-lasting hypersensitivity of similar magnitude to that observed following CCI (Supplementary Fig. 7a) . Administration of OB-1 to the plantar skin in the SNI model produced no reversal of allodynia (Supplementary Fig. 7b) . We removed the lumbar DRGs from these animals and found no change in the levels of Stoml3 mRNA between the injured and uninjured side in this model (Supplementary Fig. 7c ). This finding suggests that the effects of OB-1 in alleviating mechanical hypersensitivity may in part depend on whether STOML3 levels are upregulated.
Mechanical hyperalgesia is also a prominent feature in inflammatory pain and is largely dependent on increased nerve growth factor (NGF) levels 36 . Systemic dosing with NGF (1 mg/kg) is sufficient to provoke long-lasting mechanical and heat hyperalgesia 36, 37 , which were both unchanged in NGF-injected Stoml3 −/− mice ( Supplementary  Fig. 7d,e) . Additionally, mechanical hypersensitivity after NGF was also not reversed by local intraplantar OB-1 ( Supplementary  Fig. 7f,g ). This data is consistent with the prevailing view that NGF-dependent cutaneous mechanical hyperalgesia is primarily driven by central sensitization 36, 38 .
Regulation of Stoml3 mRNA and protein after injury
The levels of Stoml3 mRNA are very low in the DRG, and we have never found an antibody that is sensitive or specific enough to detect endogenous STOML3. We therefore generated two new knock-in mouse models to monitor Stoml3 gene expression and STOML3 protein, respectively. We created a knock-in allele in which a lacZ cassette with a nuclear localization signal was fused in frame with the start codon of the Stoml3 gene (Stoml3 lacZ mice; Supplementary  Fig. 8a-c) . This reporter allele allowed us to visualize subsets of sensory neurons that express Stoml3 (Fig. 6a) . We observed β-galactosidase staining in around half of sensory neurons with cell bodies > 20 µm in diameter, a population known to consist of mechanoreceptors (Fig. 6a) . The number of β-galactosidase-positive neurons more than doubled in the lumbar DRGs L4-L6 after a unilateral CCI challenge, and these cells were also predominantly > 20 µm in diameter (Fisher's exact test, P < 0.0001; Fig. 6b ). This data is consistent with the idea that chronic nerve constriction leads to an increase in the number of large and medium-sized sensory neurons that express higher levels of Stoml3. Consistent with our observation that Stoml3 mRNA levels are very low in the DRG, the β-galactosidase-positive cells were difficult to visualize when screening for β-galactosidase activity, and Mann-Whitney U-test: CCI ipsi vs. co, P = 0.0079; naive ipsi vs. CCI ipsi, P = 0.0357; naive ipsi vs. co, P = 0.7000. Numbers indicate RNA preparations with L4-6 of two adult mice pooled for one RNA preparation; data represent the mean copy number ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; ns, nonsignificant. a r t I C l e S antibodies directed against β-galactosidase did not stain these cells. It was therefore difficult to obtain a neurochemical profile of Stoml3 expressing sensory neurons.
In the second knock-in mouse we introduced nucleotides encoding the StrepII tag 39 3′ to the start codon ( Fig. 6c and Supplementary  Fig. 8d-f) . The genomic fusion was successful as we could amplify Stoml3 mRNA transcripts containing the nucleotide sequence encoding an N-terminally StrepII-tagged Stoml3. We carried out western blotting for the StrepII-tagged protein in Stoml3 StrepII CCI mice and extracted protein from sciatic nerve 2, 6 and 13 d after the injury. We detected a specific band (absent in Stoml3 −/− nerve) of the appropriate molecular weight in protein extracts from the sciatic nerve only (6) (6) (6) (6) (12) (6) (6) (11) a r t I C l e S after using a strong denaturing buffer containing 8M urea (Fig. 6d) . We could sometimes detect the StrepII-STOML3 band from extracts made from DRG, but this was much weaker and less reliable (data not shown). Notably, we found more intense StrepII-STOML3-positive bands on the injured side at day 2, day 6 and to a lesser extent at day 13 compared to the noninjured contralateral nerve (Fig. 6d) . The band for the neuronal marker PGP9.5 dramatically decreased in intensity on the injured side several days after injury, probably reflecting axon loss and atrophy; despite this, STOML3 levels were increased. These results suggest that endogenous STOML3 is transported preferentially to the peripheral endings of sensory neurons 40 to modulate mechanotransduction and that more STOML3 is transported to sensory endings after traumatic nerve injury.
STOML3 and painful diabetic neuropathy
Neuropathy is a prominent symptom of diabetes, affecting up to 20% of all patients, and is often characterized by pain initiated by normally innocuous tactile stimulation 41 . We asked whether OB-1 showed efficacy in a mouse model of painful diabetic neuropathy. We used the streptozotocin model (STZ) to induce mechanical hypersensitivity in mice with diabetes 42 . Between 6 and 7 weeks after STZ treatment, mice assigned to the drug group and vehicle group began to display hypersensitivity to mechanical stimuli, as reflected in increased frequency of paw withdrawal to von Frey filaments below 0.5 g (Fig. 7a-d) . Local treatment of the hindpaw glabrous skin with OB-1 (250 pmol per paw) substantially reversed the mechanical hypersensitivity 4 h after treatment, whereas vehicle treatment was without effect (paw withdrawal thresholds: OB-1 treated, 0.93 ± 0.13 g versus STZ, 0.32 ± 0.06 g; paired t-test, P = 0.0013; or vehicle-treated, 0.63 ± 0.13 g versus STZ, 0.51 ± 0.01 g; paired t-test, P = 0.31; Fig. 7a-d) . Mechanical hypersensitivity returned to pre drug treatment levels 24 h after a single treatment, as assessed by the mean 60% withdrawal threshold (Fig. 7a,b) .
DISCUSSION
Mammalian touch sensation is at last beginning to be unraveled at the molecular level 43, 44 . Mechanosensitive ion channels like Piezo1 and Piezo2 may prove difficult targets to exploit for pharmacological intervention 45 . For example, the early embryonic or postnatal lethality associated with Piezo1 or Piezo2 gene deletion 46, 47 and Piezo2's role in proprioception 11, 12, 48 could prove problematic for the development of Piezo antagonists for therapeutic purposes. Here we describe an intersectional approach to modulate sensory mechanotransduction, as our compounds should only be effective in cells in which both STOML3 and Piezo channels are present. This approach has the advantage of not directly effecting essential functions of Piezo proteins, yet our small proteins allowed selective and powerful inhibition of sensory mechanotransduction, especially under some pathophysiological conditions. We showed that OB-1 has a powerful silencing effect on around 40% of mechanoreceptors and conclude that the transformation of the mechanical stimulus into receptor potential was severely impaired in these cells. Mechanosensitive currents were also inhibited by OB-1 in some nociceptors in our in vitro studies (Fig. 2f) and, consistent with this, mechanical thresholds were significantly elevated in many cutaneous C fibers measured using the ex vivo skin-nerve preparation (Fig. 3) . We propose that STOML3 inhibition silences mechanoreceptors primarily by reducing the a r t I C l e S displacement sensitivity of Piezo2 ion channels in mechanoreceptors.
Mechanically gated currents in nociceptors may not be dependent on Piezo2 4 , but deep sequencing studies have detected Piezo1 transcripts in many single mouse sensory neurons 49 , and Piezo1 channels are also strongly modulated by STOML3 (ref.
2). Skin application of our STOML3 inhibitor OB-1 showed remarkable efficacy in reducing touch-evoked pain behavior in two mouse models of neuropathic pain but not in an SNI model. There was direct damage to the axons innervating the sensitized skin in the CCI model, which is associated with increased Stoml3 expression as well as with increased STOML3 protein transport to the periphery (Fig. 6) . Thus, we speculate that the high efficacy of OB-1 in some pain models, including painful diabetic neuropathy, was directly linked to changes in STOML3 availability at sensory endings during disease progression. Stoml3 mRNA transcript expression has been detected in human tibial nerve and skin (http://gtexportal.org/home/), and therefore it may be possible to detect changes in STOML3 in pathologies associated with neuropathic pain. In summary, we provided mechanistic validation of a pharmacological strategy for modulating sensory mechanotransduction to treat sensory disorders including pain.
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Animals.
The experiments in this study were carried out on adult inbred male or female mice (adult C57Bl/6N obtained from Charles River, Sulzfeld, Germany) or adult mice generated and breed in the laboratory (Stoml3 −/− , Stoml3 StrepII or Stoml3 lacZ ). All experiments were performed in compliance with German and European laws for the use of animals in research and with appropriate permits from the Berlin authorities (Landesamt für Gesundheit und Soziales, Berlin). Animals were kept under controlled temperature and a 12-h light, 12-h dark cycle with lights on at 06:00 a.m. or 4:00 am for tactile perception test. Behavioral tests were conducted during the light phase, and the experimenter was blinded to treatment and genotype unless otherwise stated.
Statistics. All data were tested for normal distribution. Appropriate statistical tests applied for data analysis are noted in figure legends. Multiple comparisons were performed by repeated measures two-way ANOVA followed by Bonferroni post hoc tests. Significance levels of *P < 0.05, **P < 0.01 and ***P < 0.001 were used. Statistical analyses and exponential fits were made using GraphPad Prism or Igor Pro 6.11 software. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 2, 5, 6, 10, 22, 29, 42, [50] [51] [52] [53] . Experimenters were always blinded to treatment or genotype unless otherwise stated. No special randomization procedures were used for assigning groups. molecular biology. Expression constructs. Constructs for BiFC analysis were created by inserting the gene of interest, in frame, into the multiple cloning site of pBiFC-VC155 or pBiFC-VN173. Point mutations were introduced using PCRbased site-directed mutagenesis.
RT-PCR analysis. Lumbar L4-L6 dorsal root ganglia (DRG) were dissected from CCI and control mice, pooled and total RNA extracted with the TRIzol method (Invitrogen) as per manufacturer recommendations and treated with the TURBO DNA-free Kit to avoid DNA contamination. RNA was quantified using NanoDrop 2000 UV-Vis spectrophotometer (Thermo Scientific) and reversetranscribed using SuperScript® III Reverse Transcriptase (Invitrogen). TaqMan Quantitative RT-PCR was used to detect the expression of STOML3 mRNA with 5′-GGAAGCCAGAGCCAAGGT-3′ and 5′-TGCAGGTACCGAAGTTGGA-3′ primers in combination with the TaqMan probe #53 from Roche Universal Probe Library. Each sample was performed in triplicate in an ABI Prism 7700 Sequence Detection System (Thermo Scientific).
cell culture. HEK-293 cells (passage numbers [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] were cultured in DMEM plus 10% FCS (FCS). Neuro2A (N2a) cells were cultured in DMEM/Opti-MEM media plus 10% FCS. Cell lines were originally sourced from the ATCC and regularly checked for mycoplasma contamination. Sensory DRG neurons were isolated from 4-week-old Mus musculus (C57Bl/6). Approximately 40 ganglia were collected from each mouse and individual cells were isolated by treating ganglia with 1 µg/ml collagenase IV for 30 min, followed by 1 ml of 0.05% trypsin, in PBS, for 5-20 min at 37 °C. Enzyme-treated ganglia, in DMEM/F-12 media containing 10% horse serum (HS), were disrupted by gently passaging through a 20 gauge needle; cells were then collected by centrifugation (1,000 rpm, 3 min), washed and finally resuspended in DMEM/F-12, 10% HS media (at no point were neurotrophins added to the culture). Experiments with isolated sensory neurons were conducted within 24-36 h of isolation.
High-throughput screen. HEK-293 cells were cultured to approximately 70% confluence; cells were cotransfected with plasmids encoding STOML3-VC and STOML3-VN using Fugene-HD, as per manufacturer's instructions. The transfection reaction proceeded for 8 h before cells were recovered and resuspended in DMEM media containing 25 mM HEPES and lacking phenol red. Cells were plated on PLL-coated 384 well plates using an automated dispenser (EL406 Microplate Washer Dispenser). Each well of the plates already contained one compound from the ChemBioNet library (http://www.chembionet.info/), a library containing small molecules with drug like properties 54 . Development of the YFP fluorescence signal was monitored overnight (15 h), with readings taken every 3 h (excitation: 515 ± 8 nm, emission: 535 ± 8 nm). Overnight monitoring of signal development was performed with a Freedom Evo workstation, a SafireII plate reader for fluorescence measurement (Tecan Group Ltd, Männedorf, Switzerland) and an integrated STX44-ICSA automated plate incubator (Liconic AG, Mauren, Liechtenstein). Experiments were repeated with 20 plates each day until the entire compound library had been screened and data was normalized to in-plate controls.
Compounds of interest were selected from the slope of YFP signal versus time. Each well was compared to the average slope of in-plate positive controls (normalized percent activity), and compared to the mean and s.d. of all samples on a plate (without the controls), giving a z-score as a measure of statistical significance 53 . One hundred and fifteen (115) inhibitors that significantly decreased the slope with z-scores < −3 were selected for further analysis. After rescreening in triplicate, 21 of the initially identified hit molecules were confirmed. Compounds that were themselves fluorescent or those that had significant effects on cell viability were discarded. dSToRm imaging. N2a cells were cultured on EHS-Laminin coated 0.17-mm thick precision cover glass and transfected with a STOML3-FLAG plasmid. After overnight incubation, cells were treated for 3 h with 20 µM compound or with DMSO as a control. Cells were fixed (15 min, 4% PFA), permeabilized (0.05% Triton X-100, 5 min) and blocked (phosphate buffered saline (PBS) containing 10% fetal goat serum (FGS), 37 °C, 1 h). Cells were labeled with mouse anti-FLAG antibody (M2 clone Sigma #F1804, 1:100 in PBS containing 10% FGS). The secondary antibody was an Alexa Fluor 647-conjugated, goat anti-mouse antibody (1:100 in PBS plus 10% FGS, 1 h, 37 °C). After staining, the samples were fixed again. Prior to dSTORM imaging, coverslips were mounted in dSTORM buffer PBS, pH 7.4, containing an oxygen scavenger (0.5 mg/ml glucose oxidase), 40 mg/ml catalase, 10% (w/v) glucose and 100 mM MEA 19 .
The custom-built dSTORM system, based on a Nikon Ti microscope, was described in detail previously 20 . Before acquisition, we illuminated the Alexa Fluor 647-labeled sample with 643-nm light to switch fluorophores into the OFF state. After molecules started blinking, we acquired a sequence of frames (typically 10,000-20,000) using a 100× 1.49 NA objective, a 1.5 magnification lens and nonbinned EMCCD array. An exposure time of 30 ms was used to a ensure good signal-to-noise ratio and a high number of blinking single molecules/frame.
In order to aid drift correction, PLL-coated Tetra-speck fluorescent beads were allowed to adhere to the sample overnight.
Localization. Single molecules were localized using open source software rapidSTORM 3.2 (ref. 21) . The source images were first smoothed via median operator, followed by a fill-hole operation to reduce noise. In these 'denoised' images, rapidSTORM performed a Gaussian fit (Levenberg-Marquardt parameter estimation) to each intensity spot, and fit quality and peak maxima were used as quality measures for localization. This fit yielded the precise position of the single molecule with subpixel accuracy, as well as the total intensity of the single molecule event and the frame number of the event. Sample drift was corrected using fiduciary beads in the sample as reference points (custom-written algorithm, GREGOR).
For analysis of STOML3 domain size, all reconstructed images were blinded and then 100 individual dots were cropped from each imaged cell (size: 20 × 20 pixels). A 2D Gaussian fit was calculated using Igor software (WaveMetrics, USA). The x-width and y-height for each dot were included in the data set as domains were not necessarily circular. chemical synthesis. The molecules OB-1 and OB-2 were structurally compared using a Tanimoto coefficient. The structures were translated with a FCFP-4 protocol and the resulting fingerprints did not show any significant similarity. Detailed chemical information for OB-1 and OB-2 can be found with the following links:
OB-1: http://www.chemspider.com/Chemical-Structure.948385.html and OB-2: http://www.chemspider.com/Chemical-Structure.4452133.html. For de novo synthesis, 5.6 g of ethyl-3-oxo-3-phenylpropanoate (29.06 mmol) was solubilized in 50 ml toluene and 525 mg (1.45 mmol) of Cu(OTf) 2 was added. Next, 1.57 g (14.5 mmol) of benzoquinone was solubilized in 20 ml of toluene and added dropwise to the reaction mixture followed by reflux for 3 h. The mixture was quenched with NH 4 Cl and extracted three times with ethyl acetate. The combined organic layers were washed with brine and dried with Na 2 SO 4 . The crude product was purified by chromatography on silica gel eluting with a gradient of Hex/EE (10:1) to give 2.24 g of ethyl-5-hydroxy-2-phenylbenzofuran-3-carboxylate (yield: 27%) This product was an intermediate before final synthesis of OB-1. Next 0.5 g (1.77 mmol) of ethyl-5-hydroxy-2-phenylbenzofuran-3-carboxylate was solubilized in 20 ml DMF and 1.2 eq Cs 2 CO 3 (0.7 g, 2.1 mmol), 0.1 eq CuI (33 mg, 0.17 mmol) and 285 mg (1.77 mol) 5-chloro-1-methyl-4-nitro-1H-imidazole were added. The mixture was stirred for 3 h at room temperature. The organic solvent was removed under reduced pressure. The crude product was purified by chromatography on silica gel eluting with a gradient of Hex/EE (3:2) to give 644 mg of ethyl-5-(1-methyl-4-nitro-1H-imidazol-5-yloxy)-2-phenylbenzofuran-3-carboxylate (yield: 89%).
electrophysiology. Whole-cell patch-clamp recordings were conducted as previously described 2,51 , using patch pipettes with a tip resistance of 3-6 MΩ, filled with a solution of 110 mM KCl, 10 mM NaCl, 1mM MgCl2, 1 mM EGTA and 10 mM HEPES, adjusted to pH 7.3 with KOH. For experiments on DRG neurons, 10 mM QX-314 was added to the pipette to block voltage-gated sodium channels 2 . Extracellular solutions contained 140 mM NaCl, 4 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 4 mM glucose, 10 mM HEPES, adjusted to pH 7.4 with NaOH. A Zeiss 200 inverted microscope and an EPC-10 amplifier in combination with Patchmaster software was used, and data was analyzed using Fitmaster software (HEKA Electronik GmbH, Germany). Mechanical stimuli were applied using a polished glass probe driven by the MM3A micromanipulator (Kleindiek Nanotechnik, Germany). Mechanical stimuli were applied by either indenting the cell soma or by culturing cells on elastomeric pillar arrays and applying the stimulus to the cell-substrate interface by deflecting an individual pilus. For a detailed description of experiments using pillar arrays, see ref.
2. Images of the pilus were obtained before and after deflection, and images were analyzed offline to determine the exact deflection for each data point. Images were obtained using a 40× LD objective and a CoolSNAP EZ CCD camera. The collection of stimulus-response data using pillar arrays generated data sets with variation in both x and y. In order to effectively compare groups for each cell studied, we binned response data by stimulus size in the following bins: 0-10, 10-50, 50-100, 100-250, 250-500 and 500-1,000 nm. For each cell, current amplitudes within each bin were averaged and then bins averaged between cells. We then tested for significance by testing whether the current amplitude for a given stimulation range (i.e., bin) differed between samples. To distinguish mechanoreceptors from nociceptors in the mixed population of acutely prepared DRG neurons, the shape of the generated action potential (AP) was used. For quantitative analysis of mechanosensitivity, we measured responses in the most sensitive subpopulation of mechanoreceptors with APs lacking a hump in the falling phase and a full width at half maximum (FWHM) of at least 0.7 ms (average ± s.e.m. = 0.9 ± 0.04 ms) 2 .
To test the effect of compounds on stomatin modulation of ASIC currents, CHO cells were transfected with vectors encoding stomatin and ASIC3 at a ratio of 4:1, using Lipofectamine as per the manufacturer's instructions. Cells were incubated with 20 µM OB-1 for 3 h in extracellular buffer (see above), and OB-1 was maintained in the media during electrophysiological experiments. ASIC3 channels were gated by applying solutions of pH6 and pH4, and both the transient and sustained peak current density was measured.
Ex vivo skin nerve preparation. The skin-nerve preparation was used essentially as previously described to record from single primary afferents 5 . For the electrical search protocol, a microelectrode (1 MΩ) was maneuvered to contact the epineurium of the nerve trunk, and an electrical stimulation was delivered at 1-s intervals with square wave pulses of 50-500 ms duration. In most filaments, 3-5 single units were counted. The electrical nerve stimulation was done at two distant sites of the saphenous nerve to trace electrically identified units to their receptive fields. Mechanical sensitivity of single units was tested by mechanical stimulation with a glass rod. A computer-controlled nanomotor (Kleindiek, Reutlingen, Germany) was used to apply controlled displacement stimuli of known amplitude and velocity. The probe was a stainless steel metal rod containing a force transducer, and the diameter of the flat circular contact area was 0.8 mm (Kleindiek, Reutlingen, Germany). The signal driving the movement of the linear motor and raw electrophysiological data were collected with a Powerlab 4.0 system (ADInstruments), and spikes were discriminated off-line with the spike histogram extension of the software.
Tactile perception task. Male C57Bl6/J mice were anaesthetized and a lightweight metal head-holder was implanted on the skull using glue (Loctite 401, Henkel) and dental cement (Paladur ®, Heraeus). Mice were habituated to the head-restraint and the behavioral setup over 2-3 d. Mouse licking and forepaw behavior was monitored with three custom-made capacitance sensors: a licking sensor, a rest sensor and a target sensor that provided an online monitor of paw or tongue contact. The rest sensor was a ball (diameter: 6 mm) mounted on a glass rod of 30 mm length, glued to a piezoelectric bender (PICMA ® Multilayer Piezo Bender Actuator, Physik Instrumente). The piezo generated a 30-ms cosine tactile pulse via a piezoelectric amplifier system (Sigmann Elektronik). The stimulus amplitude was calibrated with a high-speed (300 Hz) camera (Dalsa Genie HM640). The target sensor (diameter: 6 mm) had a start position of 10 mm horizontally in front of the rest sensor and was attached to a Fisso 3D articulated arm on a linear translation stage (ST9-100-2 eco-P, ITK Dr. Kassen GmbH, Germany). Mice were water restricted and given approximately 4 × 0.6 µl water rewards on condition of touching the target sensor within a defined latency from stimulus onset and licking the water dispenser. The target sensor moved to the start position at the start of a new trial and away from the mouse at the end of the trial. The intertrial interval was randomized between 7 and 13 s. White noise was played throughout the trial. The response window (rewarded stimulus-to-touch latency) was reduced during behavioral training to 500 ms during the testing session. Mice were trained with high amplitude stimuli (620 µm) and then tested in the same session with seven different stimulus amplitudes (in µm: 45, 80, 125, 170, 275, 385, 620) and with a no-stimulus trial to calculate the false alarm rate. Stimuli were presented in a randomized order. The setup was controlled with custom-written software in LabView 10.0 (National Instruments). Drug injections of OB-1 or DMSO alone were dissolved in Ringer's solution (in mM: 135 NaCl, 5 KCl, 5 HEPES, 1.8 CaCl2, 1 MgCl 2 ) to make the OB-1 and vehicle solution. Approximately 5 µl was injected into the digits with a glass micropipette and 10 µl into the palm with a Hamilton syringe. During the injection procedure, the mouse was anaesthetized with isoflurane (1.5 to 2.0% in O 2 ). The experimenter was not blinded to treatment.
To construct the psychometric curves, we first averaged the rates of pressing the target sensor within 500 ms from stimulus onset across 5 mice. Next we fitted the data with a sigmoid function in Igor Pro 6.11 (WaveMetrics): In deeply anaesthetized mice, using isoflurane delivered in 100% O 2 (Univentor 410 Anesthesia unit; Univentor, Malta), four loose silk (5/0; Catgut GmbH Markneukirchen) ligatures were placed around the sciatic nerve at the level of the right mid-thigh as described previously 6 . Spared nerve injury. In deeply anesthetized mice (see above) a skin and muscle incision was made at the thigh to reveal the sciatic trifurcation. Distal to the sciatic nerve's trifurcation, nerve pieces (2-4 mm) of the sural and common peroneal nerves were removed, leaving the tibial nerve intact. In sham controls, the surgery was performed without transecting the nerves. Wounds were closed with wound clips before anesthesia was terminated.
NGF-induced hyperalgesia. A single dose of NGF (1 µg/g body weight) was injected intraperitoneally (i.p.) into adult mice and behavioral testing was performed 6 h, 24 h, 48 h and 72 h after the injection.
Diabetic neuropathy model. Eight-week-old C57Bl/6 mice were used for diabetes experiments. Diabetes was induced using previously reported protocols 42, 55 . Briefly, six consecutive intraperitoneal injections of streptozotocin (STZ, SigmaAldrich, # S0130), 60 mg/kg body weight in citrate buffer (0.05 M, pH 4.5), were given at 24-h intervals to induce diabetes. Blood glucose was maintained between 400 and 500 mg/dL throughout the experimental period. Mechanical sensitivity was measured, and only those mice showing increased sensitivity to von Frey filaments as compared to basal sensitivity were selected for OB-1 testing. Vehicle or OB-1 (approximately 20 µl solution, 250 pmol per paw) was injected subcutaneously into the intraplantar surface of diabetic mice under mild isoflurane anesthesia, and mechanical sensitivity was measured from both injected (ipsilateral) and noninjected (contralateral) paws 4 and 24 h after the injection.
Assessing pain behavior. Mice were allowed to habituate to the testing apparatus (acrylic chambers 10 × 10 cm in size, suspended above a wired mesh grid) for 1 h before behavioral testing. Calibrated von Frey hair monofilaments (Aesthesio, set of 20 monofilaments, Ugo Basil) were applied to the plantar surface of the
